FDA grants breakthrough status to Norroy kidney cancer imaging agent
Biotechnology firm Norroy Bioscience secured Breakthrough Therapy and Fast Track designations from the US FDA on 19 August 2026 for its kidney cancer imaging product
WUXI, China - The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy and Fast Track designations to NORROY BIOSCIENCE's 68Ga-NYM096, a potential radiopharmaceutical imaging agent for PET imaging of clear cell renal cell carcinoma (ccRCC). The FDA's recognition is based on preliminary clinical data, highlighting the agent's potential to offer significant clinical advantages in diagnosing and managing ccRCC compared to current diagnostic approaches.
Clear cell renal cell carcinoma accounts for around 70%–80% of renal cell carcinoma cases. In 2026, an estimated 80,450 new cases of kidney cancer will be diagnosed in the US, with 15,160 deaths expected. NORROY's Founder and CEO, Mr. Peng Fang, expressed optimism over the clinical data and plans for further development and trials of 68Ga-NYM096, both in China and the United States.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
